Genevoyager (Wuhan) Co., Ltd. is dedicated to the development of large-scale viral vector preparation technology, offering services for gene therapy research and drug development and production. Our goal is to establish a globally leading platform for gene therapy drug research and production, promoting collaborations to make gene therapy drugs more effective, safer, and cost-efficient for the benefit of patients.

Genevoyager gene therapy CRO/CDMO service platform currently has over 300 employees, including approximately 200 research and development professionals. We operate within a total area of over 10,000 m², consisting of a 4,000 m² laboratory and a 6,400 m² cGMP workshop, which has undergone successful commissioning and commenced production in October.

Our subsidiary, BrainVTA (Wuhan) Co., Ltd., has been providing viral vector CRO services for nearly 10 years.